James E. Gregory, UPM Pharmaceuticals || October 7, 2015 Pharmaceutical and biopharmaceutical companies large and small are increasingly relying on third-party providers for support at all stages of drug development. To realize efficiencies, they are at the same time reducing the number of suppliers to a preferred few with whom they can form strategic partnerships.
Franklin Spriggs, Stephanie Mowery and Bo Kowalcyk, AIT Biosciences || October 7, 2015 ADCs are a breakthrough cancer treatment that can deliver cytotoxins directly to cancer cells without the sweeping collateral damage of traditional chemotherapy.
Anais Colin, Technical Resources International (TRI) || October 7, 2015 According to recent trends reports1, contract research organization (CRO) outsourcing is expected to grow to 35% by 2018 and up to 60% in the longer term. Due to the increasing involvement of CROs in clinical research, and their highly concentrated e…
Suhasini Sharma, Sciformix Corporation || September 11, 2015 Global biologics market will expand to $250 billion annually by 2020, with biosimilars and non-original biologics commanding 4-10% of that market